Treatment of Erythroderma in Atopic Dermatitis
This protocol addresses erythroderma arising as a complication of atopic dermatitis — a recognised pattern in which the underlying chronic inflammatory skin disease drives widespread erythrodermic involvement.
Exfoliative dermatitis in the setting of atopic dermatitis represents a clinically significant subset. The reported prevalence of exfoliative dermatitis related to atopic dermatitis ranges from 4.76% to 23.9%, underscoring the importance of a structured, evidence-based management approach specific to this combination.
When topical treatment has not achieved adequate control, first-line management involves specific light-based and/or systemic therapeutic approaches. The complete regimen — including agent selection, sequencing, and titration — is defined in the full protocol.
Goal: Clinical remission of erythrodermaReferences
DOI: 10.1016/j.adengl.2018.05.033
- It has been reported that exfoliative dermatitis related to atopic dermatitis varies from 4.76 to 23.9%.
- First-line treatment choices for adults with severe atopic dermatitis, particularly after failure with topical treatment, include narrow-band UVB phototherapy (Evidence IIB) or systemic immunosuppressant.
- Oral cyclosporine has been evaluated in randomized trials and systematic reviews showing to be an adequate short-term treatment (Evidence I-IIB).